Your browser doesn't support javascript.
loading
Structure-Activity Studies of Novel Di-substituted [1,2,5]oxadiazolo [3,4-b]pyrazine Analogs Targeting the A-loop Regulatory Site of p38 MAP Kinase.
Carrasco, Esther; Gomez-Gutierrez, Patricia; Campos, Pedro M; Vega, Miguel; Messeguer, Angel; Perez, Juan Jesus.
Afiliação
  • Carrasco E; Allinky Biopharma, Campus de Cantoblanco, Faraday 7, 28049 Madrid, Spain.
  • Gomez-Gutierrez P; Allinky Biopharma, Campus de Cantoblanco, Faraday 7, 28049 Madrid, Spain.
  • Campos PM; Dept. of Chemical Engineering, Universitat Politecnica de Catalunya, 08028 Barcelona, Spain.
  • Vega M; Allinky Biopharma, Campus de Cantoblanco, Faraday 7, 28049 Madrid, Spain.
  • Messeguer A; Allinky Biopharma, Campus de Cantoblanco, Faraday 7, 28049 Madrid, Spain.
  • Perez JJ; IQAC CSIC, Institute of Advanced Chemistry of Catalonia, Dept. Biol. Chem., Jordi Girona 18-26, 08034 Barcelona, Spain.
Curr Med Chem ; 29(9): 1640-1653, 2022.
Article em En | MEDLINE | ID: mdl-34931978
INTRODUCTION: In the quest for novel allosteric inhibitors of the p38 MAP kinase, we recently described the A-loop regulatory site, identified by means of molecular modeling studies together with the disclosure of a small molecule hit with a moderate inhibitory profile. Starting from this structure, we subsequently identified two additional hits with simpler molecular structures from an in silico screening study, using a substructure search in the SciFinder database. After corroboration of their inhibitory profile, analysis of their structures permitted to conclude about the suitability of the [1,2,5]oxadiazolo[3,4-b]pyrazine (furazano[ 3,4-b]pyrazine) scaffold for the development of potent A-loop regulatory site p38 MAP kinase inhibitors. Accordingly, we report the synthesis and pharmacological evaluation of a series of di-substituted analogs with a potent inhibitory profile of p38 MAP kinase, as shown by in vitro assays of their capability to inhibit IL-1ß secretion in human monocyte-derived macrophages. OBJECTIVE: To find small molecule potent inhibitors of the p38 MAP kinase A-loop regulatory site. METHODS: Starting from this structure, we subsequently identified two additional hits with simpler molecular structures from an in silico screening study, using a substructure search in the SciFinder database. After corroboration of their inhibitory profile, we carried out a hit-tolead optimization process guided by molecular modeling using a [1,2,5]oxadiazolo[3,4- b]pyrazine (furazano[3,4-b]pyrazine) scaffold. RESULTS: We report the synthesis and pharmacological evaluation of a series of di-substituted analogs with a potent inhibitory profile of p38 MAP kinase, as shown by in vitro assays of their capability to inhibit IL-1ß secretion in human monocyte-derived macrophages. CONCLUSION: We describe in the present work a series of [1,2,5]oxadiazolo[3,4-b]pyrazine (furazano[3,4-b]pyrazine), which are potent inhibitors of IL-1ß secretion in human monocytederived macrophages allosteric modulators of the p38 MAP kinase A-loop regulatory site.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Proteínas Quinases p38 Ativadas por Mitógeno Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pirazinas / Proteínas Quinases p38 Ativadas por Mitógeno Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article